Citadel Advisors’s Crescent Biopharma CBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-590
| Closed | -$12.4K | – | 13458 |
|
|
2025
Q1 | $12.4K | Buy |
590
+80
| +16% | +$2.14K | ﹤0.01% | 13449 |
|
|
2024
Q4 | $12.7K | Buy |
+510
| New | +$13.9K | ﹤0.01% | 13485 |
|
|
2024
Q3 | – | Sell |
-494
| Closed | -$13.9K | – | 14582 |
|
|
2024
Q2 | $13.9K | Sell |
494
-75
| -13% | -$7.8K | ﹤0.01% | 12913 |
|
|
2024
Q1 | $171K | Buy |
569
+511
| +881% | +$153K | ﹤0.01% | 10572 |
|
|
2023
Q4 | $13.7K | Buy |
+58
| New | +$9.02K | ﹤0.01% | 12918 |
|
|
2023
Q3 | – | Sell |
-160
| Closed | -$27.8K | – | 14592 |
|
|
2023
Q2 | $27.8K | Sell |
160
-1,439
| -90% | -$241K | ﹤0.01% | 12429 |
|
|
2023
Q1 | $201K | Buy |
1,599
+328
| +26% | +$73.8K | ﹤0.01% | 10171 |
|
|
2022
Q4 | $385K | Buy |
+1,271
| New | +$187K | ﹤0.01% | 8800 |
|
|
2022
Q2 | – | Sell |
-202
| Closed | -$23K | – | 13314 |
|
|
2022
Q1 | $23K | Sell |
202
-1,195
| -86% | -$140K | ﹤0.01% | 13208 |
|
|
2021
Q4 | $201K | Sell |
1,397
-919
| -40% | -$167K | ﹤0.01% | 11842 |
|
|
2021
Q3 | $507K | Sell |
2,316
-287
| -11% | -$60.8K | ﹤0.01% | 9825 |
|
|
2021
Q2 | $604K | Buy |
2,603
+785
| +43% | +$200K | ﹤0.01% | 9606 |
|
|
2021
Q1 | $547K | Buy |
1,818
+1,464
| +414% | +$524K | ﹤0.01% | 9479 |
|
|
2020
Q4 | $133K | Sell |
354
-146
| -29% | -$51.2K | ﹤0.01% | 10022 |
|
|
2020
Q3 | $154K | Buy |
+500
| New | +$191K | ﹤0.01% | 8984 |
|
|
2019
Q4 | – | Sell |
-131
| Closed | -$56K | – | 9344 |
|
|
2019
Q3 | $56K | Buy |
+131
| New | +$84.3K | ﹤0.01% | 8672 |
|
|
2019
Q2 | – | Sell |
-125
| Closed | -$156K | – | 9417 |
|
|
2019
Q1 | $156K | Buy |
+125
| New | +$143K | ﹤0.01% | 8367 |
|
|
2018
Q2 | – | Sell |
-103
| Closed | -$167K | – | 8988 |
|
|
2018
Q1 | $167K | Buy |
+103
| New | +$214K | ﹤0.01% | 7474 |
|
Other funds holding CBIO
BI
FFM
VA
FIS
VPC
OM
TCM
ACM
LGM